A paper in the International Journal of Cancer offers information on the sequencing of cabazitaxel (CAB) and abiraterone acetate (ABI) in men with metastatic, castration-resistant prostate cancer (mCRPC) who have already progressed after treatment with docetaxel. The co-called cabazitaxel and abiraterone sequential treatment (CAST) study was based on a retrospective analysis of data from men with […]Image may be NSFW.
Clik here to view.
Clik here to view.
